医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau’s Achievement of a Major Milestone in China Strategy

2017年11月03日 AM01:40
このエントリーをはてなブックマークに追加


 

BOSTON

Sinotau Pharmaceuticals has announced today an agreement with HTA CO. LTD for launching a new β-amyloid imaging agent for Alzheimer’s disease in China.

“This agreement will greatly contribute to the successful launch of future products in China. It is expected that this new product will be used to treat patients by delivering the latest diagnostic technologies as well as contributing to developing therapies for Alzheimer’s disease. Sinotau Pharmaceuticals is devoted to develop the latest global nuclear medicine products for use in China,” says Xinsheng Xu, President and CEO of Sinotau Pharmaceuticals. “We are excited by this opportunity to cooperate with the largest Radiopharmaceutical production enterprise in China to accelerate the process of launching innovative drugs in the market and exploring pathways that strengthen and expand the radiopharmaceutical market in China.”

“HTA CO. LTD has considerably expanded the construction of a Radiopharmaceutical network and is focusing on the development and access of new technologies,” says Guomin Fan, president of HTA CO. LTD. “As a result of cooperating with Sinotau Pharmaceuticals there will be more opportunities to obtain novel technologies in the industry. Our collaboration will begin with encephalopathy and cardiovascular diseases widely known in the world.”

About Sinotau Pharmaceuticals

Sinotau Pharmaceuticals is listed on the NEEQ (stock code: 838851) and has a focus on developing the latest radiopharmaceuticals with integrated domestic and international resources. Sinotau has signed development rights for MK-6240 in China and other novel products for domestic purposes. Furthermore, through Sinotau’s partnership with Cerveau Technologies, Inc, collaborations have been developed with multiple pharmaceutical companies to support therapy development utilizing molecular imaging biomarkers.

About HTA CO. LTD

HTA CO. LTD is a company listed on the NEEQ (stock symbol: 430005). It is the biggest subsidiary of China Tongfu Stock Co., Ltd., focused on Radiopharmaceuticals and devoted to industrialize the application of nuclear technology. HTA CO. LTD owns the largest manufacturing portfolio and research network for radioactive isotopic preparation in China. Corresponding pharmaceutical sites and hospital centers have been established throughout the country.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102006261/en/

CONTACT

Sinotau Pharmaceuticals
Xianghong Zou
18610482588
sinotau@sinotau.com
or
Cerveau
Technologies, Inc.

Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease